Investigative and Clinical Urology

The Korean Urological Association (대한비뇨의학회)
권호 표지
DOI QR코드

DOI QR Code

Renal function is associated with prognosis in stent-change therapy for malignant ureteral obstruction

  • Yoon, Ji Hyung (Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Park, Sejun (Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Park, Sungchan (Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Moon, Kyung Hyun (Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Cheon, Sang Hyeon (Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Kwon, Taekmin (Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine)
  • Received : 2018.09.09
  • Accepted : 2018.10.15
  • Published : 2018.11.10
⟨ Previous Next ⟩

Abstract

Purpose: The authors performed this study to investigate the risk factors for predicting stent failure and to evaluate its impact on prognosis. Materials and Methods: Between January 2002 and March 2017, we retrospectively reviewed 117 consecutive patients who underwent retrograde ureteral stenting and exchanging at least once every 3 months for malignant ureteral obstruction. The patients were classified according to their pre-stenting chronic kidney disease (CKD) stage. The factors affecting stent failure were analyzed using a logistic regression model. Overall survival (OS) was estimated, and the prognostic significance of each variable was estimated using Cox proportional-hazards regression modeling. Results: Before stenting, 91 patients were CKD stages 1-3 and 26 patients were CKD stages 4-5. These two groups differed significantly only in pre-stenting estimated glomerular filtration rate (eGFR), bilateral obstruction, and pre-stenting pyuria. Among the 117 patients, stent failure occurred in 30 patients (25.6%), and there were no differences between the groups. Pre-stenting pyuria and post-stenting complications were significant predictors of stent failure. There were 79 deaths in total, including 56 in the CKD stages 1-3 group and 23 in the CKD stages 4-5 group. In the multivariate analysis predicting patient OS, pre-stenting eGFR and post-stenting disease progression were significant factors. Conclusions: Internal ureteral stenting was effective for maintaining renal function in malignant ureteral obstruction. However, it did not restore renal function, which is related to the prognosis of the patients. Therefore, to improve patients' renal function and prognosis, patients who require stenting must be quickly recognized and treated.

Keywords

References

  1. Rosenberg BH, Bianco FJ Jr., Wood DP Jr, Triest JA. Stentchange therapy in advanced malignancies with ureteral obstruction. J Endourol 2005;19:63-7. https://doi.org/10.1089/end.2005.19.63
  2. Yachia D. Recent advances in ureteral stents. Curr Opin Urol 2008;18:241-6. https://doi.org/10.1097/MOU.0b013e3282f46d81
  3. Liatsikos EN, Karnabatidis D, Katsanos K, Kallidonis P, Katsakiori P, Kagadis GC, et al. Ureteral metal stents: 10-year experience with malignant ureteral obstruction treatment. J Urol 2009;182:2613-7. https://doi.org/10.1016/j.juro.2009.08.040
  4. Hafron J, Ost MC, Tan BJ, Fogarty JD, Hoenig DM, Lee BR, et al. Novel dual-lumen ureteral stents provide better ureteral flow than single ureteral stent in ex vivo porcine kidney model of extrinsic ureteral obstruction. Urology 2006;68:911-5. https://doi.org/10.1016/j.urology.2006.05.025
  5. Song SH, Pak S, Jeong IG, Kim KS, Park HK, Kim CS, et al. Outcomes of stent-change therapy for bilateral malignancyrelated ureteral obstruction. Int Urol Nephrol 2015;47:19-24. https://doi.org/10.1007/s11255-014-0858-z
  6. Sountoulides P. Are metal ureteral stents indicated in cases of benign upper urinary tract obstruction? Indian J Urol 2011;27:305-6. https://doi.org/10.4103/0970-1591.85419
  7. Aravantinos E, Anagnostou T, Karatzas AD, Papakonstantinou W, Samarinas M, Melekos MD. Percutaneous nephrostomy in patients with tumors of advanced stage: treatment dilemmas and impact on clinical course and quality of life. J Endourol 2007;21:1297-302. https://doi.org/10.1089/end.2006.0104
  8. Andriole GL, Bettmann MA, Garnick MB, Richie JP. Indwelling double-J ureteral stents for temporary and permanent urinary drainage: experience with 87 patients. J Urol 1984;131:239-41. https://doi.org/10.1016/S0022-5347(17)50324-9
  9. Chung SY, Stein RJ, Landsittel D, Davies BJ, Cuellar DC, Hrebinko RL, et al. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol 2004;172:592-5. https://doi.org/10.1097/01.ju.0000130510.28768.f5
  10. Hyppolite JC, Daniels ID, Friedman EA. Obstructive uropathy in gynecologic malignancy. Detrimental effect of intraureteral stent placement and value of percutaneous nephrostomy. ASAIO J 1995;41:M318-23. https://doi.org/10.1097/00002480-199507000-00022
  11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461-70. https://doi.org/10.7326/0003-4819-130-6-199903160-00002
  12. Russo P. Ureteral obstruction and stents: still a difficult problem for patients and urologists alike. J Urol 2005;174:2088. https://doi.org/10.1097/01.ju.0000187105.30751.77
  13. Ganatra AM, Loughlin KR. The management of malignant ureteral obstruction treated with ureteral stents. J Urol 2005;174:2125-8. https://doi.org/10.1097/01.ju.0000181807.56114.b7
  14. Yu SH, Ryu JG, Jeong SH, Hwang EC, Jang WS, Hwang IS, et al. Predicting factors for stent failure-free survival in patients with a malignant ureteral obstruction managed with ureteral stents. Korean J Urol 2013;54:316-21. https://doi.org/10.4111/kju.2013.54.5.316
  15. Wolf JS Jr. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. Int Braz J Urol 2004;30:340-1.
  16. Harrington KJ, Pandha HS, Kelly SA, Lambert HE, Jackson JE, Waxman J. Palliation of obstructive nephropathy due to malignancy. Br J Urol 1995;76:101-7. https://doi.org/10.1111/j.1464-410X.1995.tb07841.x
  17. Zadra JA, Jewett MA, Keresteci AG, Rankin JT, St Louis E, Grey RR, et al. Nonoperative urinary diversion for malignant ureteral obstruction. Cancer 1987;60:1353-7. https://doi.org/10.1002/1097-0142(19870915)60:6<1353::AID-CNCR2820600632>3.0.CO;2-5
  18. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271-89. https://doi.org/10.3322/caac.21349

Cited by

  1. Management and treatment options when facing malignant ureteral obstruction vol.27, pp.7, 2018, https://doi.org/10.1111/iju.14235
  2. 10-Year Experience with Reinforced Ureteral Stents for Malignant Ureteral Obstruction vol.13, pp.None, 2018, https://doi.org/10.2147/rru.s326274
  3. Analysis of Ureteral Tumour Stents for Malignant Ureteral Obstruction: Towards Reshaping an Optimal Stent vol.13, pp.None, 2018, https://doi.org/10.2147/rru.s334277
  4. Clinical Outcomes After Urinary Diversion for Malignant Ureteral Obstruction Secondary to Non-urologic Cancer: An Analysis of 778 Cases vol.28, pp.4, 2021, https://doi.org/10.1245/s10434-020-09423-4